gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

HRAS-like suppressor

Top mentioned proteins: HAD, CAN, MHC, AGE, POLYMERASE
Papers on ACI
Therapeutic strategies for Alzheimer's disease in clinical trials.
Malawska et al., Kraków, Poland. In Pharmacol Rep, Feb 2016
Ongoing clinical trials with Aβ antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials.
Chondrocytes co-cultured with Stromal Vascular Fraction of adipose tissue present more intense chondrogenic characteristics than with Adipose Stem Cells.
Karperien et al., Chengdu, China. In Tissue Eng Part A, Feb 2016
UNASSIGNED: Partly replacement of chondrocytes by stem cells has been proposed to improve the performance of autologous chondrocytes implantation (ACI).
Microfluidics‑based optimization of neuroleukin‑mediated regulation of articular chondrocyte proliferation.
Liu et al., Dalian, China. In Mol Med Report, Jan 2016
Autologous chondrocyte implantation (ACI) is a cell based therapy that relies on the in vitro expansion of healthy chondrocytes from the patient, during which proliferation‑promoting factors are frequently used.
Immunomodulatory Effects of Different Cellular Therapies of Bone Marrow Origin on Chimerism Induction and Maintenance Across MHC Barriers in a Face Allotransplantation Model.
Siemionow et al., Cleveland, United States. In Arch Immunol Ther Exp (warsz), Jan 2016
Twenty-four fully MHC-mismatched hemiface transplantations were performed between ACI (RT1(a)) donors and Lewis (RT1(l)) recipients under combined seven-day immunosuppressive regimen of anti-αβ-T-cell receptor (TCR) monoclonal antibody and cyclosporin A. We studied four experimental groups-group 1: no cellular therapy; group 2: supportive therapy with BMC; group 3: supportive therapy with MSC; group 4: supportive therapy with CC generated in a primary chimera.
Cartilage Repair in the Inflamed Joint: Considerations for Biological Augmentation Toward Tissue Regeneration.
Nakamura et al., Milano, Italy. In Tissue Eng Part B Rev, Jan 2016
The use of a Tissue Therapy strategy, based on more mature engineered tissues, holds promise to tackle limitations of standard ACI procedures.
Molecular evaluation of thrombosis using X-ray phase contrast imaging with microbubbles targeted to P-selectin in mice.
Chen et al., Shanghai, China. In Eur Radiol, Jan 2016
RESULTS: PCI clearly showed the microbubbles not viewable via absorption contrast imaging (ACI).
Resistance Potential of Bread Wheat Genotypes Against Yellow Rust Disease Under Egyptian Climate.
Amein et al., Asyūţ, Egypt. In Plant Pathol J, Dec 2015
Five RILs expressed hypersensitive type of resistance (R) against the pathogen and showed the lowest Average Coefficient of Infection (ACI).
A preliminary study of paraoxonase-1 in infected patients with an indwelling central venous catheter.
Camps et al., Reus, Spain. In Clin Biochem, Dec 2015
RESULTS: Patients with an acute concomitant infection (ACI) had higher CCL2, CRP and procalcitonin concentrations than the control group, together with lower paraoxonase and lactonase activities and specific activities.
Longitudinal Study of Age-Related Cataract Using Dynamic Light Scattering: Loss of α-Crystallin Leads to Nuclear Cataract Development.
Stark et al., Tokyo, Japan. In Ophthalmology, Dec 2015
METHODS: All patients underwent a comprehensive dilated eye examination every 6 months, including slit-lamp grading of their lenses using the Age-Related Eye Disease Study (AREDS) clinical lens grading system and obtaining an estimate of unbound α-crystallin level in the nucleus, the α-crystallin index (ACI), using the National Aeronautics and Space Administration-National Eye Institute DLS device.
Defect type, localization and marker gene expression determines early adverse events of matrix-associated autologous chondrocyte implantation.
Zellner et al., Regensburg, Germany. In Injury, Oct 2015
INTRODUCTION: Since the first description of autologous chondrocyte implantation (ACI) in 1994 different methods and improvements were established for this regenerative treatment option of large chondral defects.
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Chiriva-Internati et al., Lubbock, United States. In Int Rev Immunol, Mar 2015
This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.
Invited review: Drug development for tauopathies.
Grüninger, Basel, Switzerland. In Neuropathol Appl Neurobiol, Feb 2015
Many different approaches to treating tauopathies are currently being explored, with a few compounds already in clinical development (including small molecules such as anti-aggregation compound LMTX and active vaccines AADvac1 and ACI-35).
Cytogenetic Assessment of the Rat Cell Line CLS-ACI-1: An in vitro Cell Model for Mycn Overexpression.
Chaves et al., Vila Real, Portugal. In Cytogenet Genome Res, 2014
Here, we present the cytogenetic characterization and gene expression analysis of the tumoral mammary rat cell line CLS-ACI-1.
The HRASLS (PLA/AT) subfamily of enzymes.
Duncan et al., Waterloo, Canada. In J Biomed Sci, 2014
The H-RAS-like suppressor (HRASLS) subfamily consists of five enzymes (1-5) in humans and three (1, 3, and 5) in mice and rats that share sequence homology with lecithin:retinol acyltransferase (LRAT).
Activin A/BMP2 chimera AB235 drives efficient redifferentiation of long term cultured autologous chondrocytes.
Marchal et al., Granada, Spain. In Sci Rep, 2014
Autologous chondrocyte implantation (ACI) depends on the quality and quantity of implanted cells and is hindered by the fact that chondrocytes cultured for long periods of time undergo dedifferentiation.
Enzymological analysis of the tumor suppressor A-C1 reveals a novel group of phospholipid-metabolizing enzymes.
Ueda et al., Japan. In J Lipid Res, 2011
a possible enzyme activity of A-C1
Solution structure of the N-terminal catalytic domain of human H-REV107--a novel circular permutated NlpC/P60 domain.
Xia et al., Beijing, China. In Febs Lett, 2010
The phospholipase active site possesses a structurally conserved Cys-His-His triad as found in NlpC/P60 peptidases, indicating H-REV107 should adopt a similar catalytic mechanism towards phospholipid substrates to that of NlpC/P60 peptidases.
share on facebooktweetadd +1mail to friends